Form 4: Heron Therapeutics Executive Granted 500,000 Restricted Stock Units
SEC Form 4 Filing
Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, received 500,000 restricted stock units on May 6, 2025, according to a Form 4 filing.
Summary
- Mark Earl Hensley, the Chief Operating Officer of Heron Therapeutics, Inc., was granted 500,000 restricted stock units on May 6, 2025.
- The restricted stock units vest with 25% upon the first anniversary of the grant date (May 6, 2025) and then in twelve (12) equal quarterly installments thereafter.
- Following the transaction, Hensley beneficially owns 500,000 derivative securities.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Positives
- The grant of restricted stock units aligns the executive's interests with those of the shareholders.
Industry Context
Executive compensation through stock grants is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with shareholders.
Stakeholder Impact
- The grant of restricted stock units could have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/06/2025 | Date of earliest transaction (grant date of restricted stock units) |
| 05/06/2025 | First vesting date of 25% of the restricted stock units |
| 05/07/2025 | Date of Form 4 filing |
Keywords
restricted stock units, Form 4, Heron Therapeutics, HRTX, Mark Earl Hensley, executive compensation, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.